Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 6/20 | 0.54 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499215 | 0.78 | CTSV (0.63) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL31457901 | 0.77 | CTSV (0.58) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL4764681 | 0.77 | CTSV (0.67) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL1161271 | 0.77 | CTSV (0.58) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL1162107 | 0.77 | CTSV (0.58) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL31716577 | 0.77 | CTSV (0.58) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL19211147 | 0.77 | CTSV (0.58) | CTSVCTSLLMNAHTTMAPK1 | |
| Hydrochloric Acid SCHEMBL19211248 | 0.76 | CTSV (0.56) | CTSVCTSLLMNAHTTMAPK1 | |
| SCHEMBL325463 | 0.75 | LOXL2 (0.58) | AHR | |
| SCHEMBL31105584 | 0.75 | LOXL2 (0.58) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
| CN-117224534-A | Lactam for treating skin lesions | 联合利华知识产权控股有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023227856-A1 | AN ELECTROCHEMICAL SENSOR AND METHOD FOR DETECTING PATHOGENIC METABOLITES | UNIVERSITY OF DURHAM (GB) | 2023-11-30 | — | — | WO | disclosed |
| US-20230106506-A1 | NOVEL PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2023-04-06 | — | — | US | disclosed |
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | Universität Konstanz (DE) | 2023-03-07 | — | — | US | disclosed |
| EP-4085057-A1 | NOVEL PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-11-09 | — | — | EP | disclosed |
| US-20210393586-A1 | Compounds for Use in the Treatment of Bacterial Infections | Universität Konstanz (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-11160787-B2 | 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections | CONOPCO, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11083706-B2 | Lactams for use in the treatment of skin lesions | CONOPCO, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2598651-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | Sanofi-Aventis Deutschland GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123360-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| WO-2012154651-A2 | MOLECULAR ROADBLOCKS FOR RPON BINDING SITES | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012013621-A1 | METHODS AND USES RELATING TO THE IDENTIFICATION OF COMPOUND ASSOCIATED WITH BACTERIAL INFECTION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
| EP-2412819-A1 | Methods and uses relating to the identification of compound associated with bacterial infection | Sanofi-Aventis Deutschland GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110172826-A1 | Device including altered microorganisms, and methods and systems of use | SEARETE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110046195-A1 | Non-Lactone Carbocyclic and Heterocyclic Antagonists and Agonists of Bacterial Quorum Sensing | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2011-02-24 | — | — | US | disclosed |
| US-20110028945-A1 | Device including altered microorganisms, and methods and systems of use | SEARETE LLC, | 2011-02-03 | — | — | US | disclosed |
| US-20110027181-A1 | Device including altered microorganisms, and methods and systems of use | SEARETE LLC | 2011-02-03 | — | — | US | disclosed |
| WO-2007008769-A2 | USE OF PSEUDAN AND PSEUDAN INCLUSION BODIES | GEORGE MASON UNIVERSITY (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046195-A1 | Non-Lactone Carbocyclic and Heterocyclic Antagonists and Agonists of Bacterial Quorum Sensing | BID, HCAR1, HCAR2 | CTSV 3040/4885CTSL 1129/4885LMNA 4349/4885 |
| US-11596626-B2 | Compound for use against pathogenic Neisseria and Haemophilus species and Moraxella catarrhalis | MLEC, MPO, B3GNT2 | CTSV 2179/4885CTSL 2051/4885LMNA 1268/4885 |
| US-20110027181-A1 | Device including altered microorganisms, and methods and systems of use | DNASE1, MTREX, POLI | CTSV 2870/4885CTSL 1662/4885LMNA 1919/4885 |
| US-20230106506-A1 | NOVEL PqsR INVERSE AGONISTS | QRFPR, P2RY11, GPR55 | CTSV 4217/4885CTSL 3568/4885LMNA 4627/4885 |
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | CTSV 3799/4885CTSL 2876/4885LMNA 4546/4885 |
| US-20210393586-A1 | Compounds for Use in the Treatment of Bacterial Infections | BLVRB, ELANE, BPGM | CTSV 2958/4885CTSL 1874/4885LMNA 4425/4885 |
| US-11083706-B2 | Lactams for use in the treatment of skin lesions | CUTA, MGAM, DPM1 | CTSV 646/4885CTSL 579/4885LMNA 2819/4885 |
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | CTSV 3799/4885CTSL 2876/4885LMNA 4546/4885 |
| US-11160787-B2 | 4-(4-chlorophenyl)-5-methylene-pyrrol-2-one and 5-methylene-4-(p-tolyl)pyrrol-2-one for use in the treatment of gram negative bacterial infections | PGLS, PNKP, PPIL4 | CTSV 1767/4885CTSL 173/4885LMNA 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.